Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05374447 · ClinicalTrials.gov registry record · NA

Diagnostic Yield of Intranodal Forceps Biopsies in Mediastinal Adenopathy

A NA study of Sarcoidosis, Pulmonary and Mediastinal Lymphadenopathy, sponsored by George Washington University.

Recruiting
Registry status
NA
Development phase
55
Enrollment target
1
Study location

NCT05374447 is a NA study of Sarcoidosis, Pulmonary and Mediastinal Lymphadenopathy that is actively recruiting participants, run by George Washington University. The registered enrollment target is 55 participants, below the 88-participant average among 3 other Sarcoidosis, Pulmonary trials with a reported enrollment target (37% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05374447, a NA study of Sarcoidosis, Pulmonary and Mediastinal Lymphadenopathy, is actively recruiting participants, sponsored by George Washington University.

RECRUITING
Registry status
NA
Development phase
55 participants
Enrollment target
1
Study location

Study Summary

The investigators will compare endobronchial ultrasound transbronchial needle aspiration (EBUS-TBNA) with intranodal forceps biopsy (EBUS-IFB) as it relates to the rate of diagnosis of suspected sarcoidosis.

Interventions

  • PROCEDURE Endobronchial Ultrasound-Guided Intranodal Forceps Biopsy

Study Locations (1)

District of Columbia

  • The George Washington University Hospital - Washington D.C.

Trial Details

FieldValue
Enrollment Target 55 participants
Start Date 2022-06-10
Est. Completion 2026-03-01
Phase NA

Sponsor

George Washington University

133 total trials

What the Registry Record Tells You About NCT05374447

The ClinicalTrials.gov registry entry for NCT05374447 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 55 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 88-participant average among 3 other Sarcoidosis, Pulmonary trials with a reported enrollment target (37% lower). The listed sponsor is George Washington University, which has 133 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Sarcoidosis, Pulmonary appearing as the primary indexed condition, and to 1 intervention - of which Endobronchial Ultrasound-Guided Intranodal Forceps Biopsy is the first listed.

NCT05374447 reports 1 study location spanning 1 distinct geographic area - top geographies include District of Columbia.

Frequently Asked Questions

What is clinical trial NCT05374447 about?

NCT05374447 is a clinical study titled "Diagnostic Yield of Intranodal Forceps Biopsies in Mediastinal Adenopathy". The investigators will compare endobronchial ultrasound transbronchial needle aspiration (EBUS-TBNA) with intranodal forceps biopsy (EBUS-IFB) as it relates to the rate of diagnosis of suspected sarcoidosis.

What is the current status of trial NCT05374447?

This trial is currently recruiting. It is a NA study. The enrollment target is 55 participants. The study started on 2022-06-10. Estimated completion is 2026-03-01.

What conditions does trial NCT05374447 study?

This clinical trial studies the following conditions: Sarcoidosis, Pulmonary, Mediastinal Lymphadenopathy, Mediastinal Diseases.

What interventions are being tested in trial NCT05374447?

The interventions under investigation include: Endobronchial Ultrasound-Guided Intranodal Forceps Biopsy (PROCEDURE).

Who is sponsoring clinical trial NCT05374447?

This trial is sponsored by George Washington University, which has 133 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05374447 being conducted?

This trial has 1 study location across District of Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Sarcoidosis, Pulmonary

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.